MX2021012952A - Vacuna klebsiella y metodos de uso. - Google Patents

Vacuna klebsiella y metodos de uso.

Info

Publication number
MX2021012952A
MX2021012952A MX2021012952A MX2021012952A MX2021012952A MX 2021012952 A MX2021012952 A MX 2021012952A MX 2021012952 A MX2021012952 A MX 2021012952A MX 2021012952 A MX2021012952 A MX 2021012952A MX 2021012952 A MX2021012952 A MX 2021012952A
Authority
MX
Mexico
Prior art keywords
compositions
methods
protein
negative bacteria
gram negative
Prior art date
Application number
MX2021012952A
Other languages
English (en)
Inventor
Rodrigo Bicalho
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of MX2021012952A publication Critical patent/MX2021012952A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones y métodos que incluyen una proteína yidR de K. pneumoniae o un segmento antigénico de la proteína, y homólogo de la proteína, y segmentos antigénicos de los homólogos. Las composiciones se pueden presentar como formulaciones de vacunas para su uso con seres humanos y animales no humanos, incluidas, entre otras, vacas lecheras. Las composiciones y los métodos son útiles para la profilaxis y/o terapia de afecciones asociadas con bacterias Gramnegativas que incluyen K) neumonía, E. coli y otras bacterias Gramnegativas patógenas. Las condiciones incluyen tales infecciones bacterianas en general, e incluyen específicamente mastitis y metritis. Las composiciones y métodos también pueden mejorar la fertilidad y la producción de leche. La administración de las composiciones puede mejorar la probabilidad de una concepción del primer servicio.
MX2021012952A 2019-04-26 2020-04-27 Vacuna klebsiella y metodos de uso. MX2021012952A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839017P 2019-04-26 2019-04-26
US202062979795P 2020-02-21 2020-02-21
PCT/US2020/030038 WO2020220014A1 (en) 2019-04-26 2020-04-27 Klebsiella vaccine and methods of use

Publications (1)

Publication Number Publication Date
MX2021012952A true MX2021012952A (es) 2022-01-04

Family

ID=72941798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012952A MX2021012952A (es) 2019-04-26 2020-04-27 Vacuna klebsiella y metodos de uso.

Country Status (9)

Country Link
US (1) US20220257743A1 (es)
EP (1) EP3959221A4 (es)
CN (1) CN114269765A (es)
AU (1) AU2020263592A1 (es)
BR (1) BR112021021443A2 (es)
CA (1) CA3138237A1 (es)
MX (1) MX2021012952A (es)
WO (1) WO2020220014A1 (es)
ZA (1) ZA202108213B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113267481B (zh) * 2021-07-20 2021-10-08 常州罗盘星检测科技有限公司 一种溶解氧的校准系统
WO2024050452A2 (en) * 2022-08-30 2024-03-07 Administrators Of The Tulane Educational Fund Compositions and methods for raising immune responses to gram-negative bacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
CA2991907A1 (en) * 2015-07-10 2017-01-19 Douglas T. Burkhardt Proteins and immunizing compositions containing klebsiella proteins and methods of use

Also Published As

Publication number Publication date
EP3959221A1 (en) 2022-03-02
CA3138237A1 (en) 2020-10-29
EP3959221A4 (en) 2024-01-10
BR112021021443A2 (pt) 2021-12-21
CN114269765A (zh) 2022-04-01
US20220257743A1 (en) 2022-08-18
WO2020220014A1 (en) 2020-10-29
AU2020263592A1 (en) 2021-11-18
ZA202108213B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
Tiwari et al. Trends in therapeutic and prevention strategies for management of bovine mastitis: an overview
MX2022009575A (es) Una composicion que comprende bacteria y/o oligosacaridos de la leche de mamiferos (mmo) para usarse en el tratamiento y mantenimiento de la salud de un mamifero.
MX2021012952A (es) Vacuna klebsiella y metodos de uso.
NZ706636A (en) Probiotic and prebiotic compositions
PH12017500708A1 (en) Probiotic and prebiotic compositions
WO2018231992A3 (en) METHODS OF USING LACTOBACILLUS PLANTARUM STRAINS TO PROTECT ANIMALS AGAINST PATHOGENIC BACTERIAL INFECTION
Gurjar et al. Evaluation of an alternative dosing regimen of a J-5 mastitis vaccine against intramammary Escherichia coli challenge in nonlactating late-gestation dairy cows
MX366894B (es) Composiciones antimicrobianas y métodos para su producción.
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
WO2015128366A3 (en) A method for improving maize digestibility in bovine animals
Rahman et al. Isolation and identification of bacterial agents causing clinical mastitis in cattle in Mymensingh and their antibiogram profile.
Mir et al. Clinical mastitis by Streptococcus equi Subsp. zooepidemicus in goats of Jammu
Younis et al. Phenotypic and molecular characterization hemolysins of Staphylococcus aureus isolated from mastitic cow’s milk in Egypt
WO2022220699A3 (en) A bacteriophage preparation in the form of gel to prevent or treat bacterial infections in dairy cattle, its manufacturing method and bacteriophage strains
Guccione et al. Effects of systemic dry primiparous Mediterranean buffalo (Bubalus bubalis) treatment with penethamate hydriodide on udder health and milk yields.
Kocina et al. Udder health in relation to cow's seasonal keeping.
PL416204A1 (pl) Nowe szczepy bakterii fermentacji mlekowej do zwalczania Escherichia coli i Clostridium perfringens u zwierząt, zwłaszcza u przeżuwaczy, ich kompozycje i zastosowania
Van Houten The future of mastitis control
Peer et al. Studies on caprine gangrenous mastitis
YA Al-Dabbagh Bovine mastitis caused by gram negative bacteria in Mosul
Kour et al. Genotypic Characterization of Cow Heifer’s Mastitis Origin Bacteria and Nano-Particles based Approach for Effective Management of Mastitis in Dairy Animals
Gāliņa et al. The prevalence of Staphylococcus aureus in home made milk products.
Angelovski et al. Mastitis in dairy goats: isolated microorganisms and antimicrobial resistance [Conference poster].
Shahid Javed et al. Comparative prevalence of streak canal and intramammary microorganisms and their contemporaneous association in a dairy cow and buffalo herd lacking mastitis control program.
Borngern et al. The evaluation of clinical mastitis treatment cure.